Nephrotic Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments

The growth in the pipeline of nephrotic syndrome is attributed to the increase in prevalence of individuals affected with diabetes, hypertension and hyperlipidaemia. Unhealthy lifestyle and unhygienic crops and fruits are also the factors that are contributing to the growth of therapeutic pipeline of nephrotic syndrome. Environmental factors are also thought to be responsible for occurrence of nephrotic syndrome. Funds from various organizations are contributing to the research and developments in the therapy area which in turn is believed to help in early diagnosis of the disease.

Explore Report at: www.psmarketresearch.com/market-analysis/nephrotic-syndrome-therapeutics-pipeline-analysis

Nephrotic syndrome is a collection of symptoms such as, proteinuria, hyperlipidemia, edema or swelling and hypoalbuminia, which mainly affects kidneys. Edema is caused when albumin leaks into the urine and body loses its capacity to absorb its extra fluid. The anomalies in kidney filters, glomeruli, is the main risk factor of nephrotic syndrome. Tiny blood vessels in glomeruli removes waste and excess fluid from blood and direct them to urinary bladder in the form of urine. Nephrotic syndrome can also be caused by metabolic disease such as diabetes and lupus. Weight gain, fatigue, foamy urine and loss of appetite are the main symptoms observed in patients with nephrotic syndrome. Complication associated with nephrotic syndrome are hypothyroidism, anemia, coronary artery disease or coronary heart disease, high blood pressure or hypertension and acute kidney injury.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/nephrotic-syndrome-therapeutics-pipeline-analysis/toc-sample

In 2014, Anthera Pharmaceuticals, Inc. and Zenyaku Kogyo Co., Ltd. of Japan entered a license agreement, under the terms of which Zenyaku Kogyo Co., Ltd. got the rights for the development and commercialization of subcutaneous blisibimod in Japan and potentially in other Asian countries. In October 2014, the National Institutes of Health announced to provide funding of $5.8 million over a five-year period to the Nephrotic Syndrome Study Network, also known as NEPTUNE.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the companies having a pipeline of nephrotic syndrome therapeutics include, F. Hoffmann-La Roche AG, Asahi Kasei Pharma Corporation, Mallinckrodt LLC, Novartis AG, Bristol-Myers Squibb Company, Genentech, Inc., Bellus Health Inc., GlaxoSmithKline plc, Retrophin, Inc., Concert Pharmaceuticals Inc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.